| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_278d933a3f1b2e284692bc98f81bceb7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00511
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00589
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-0212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N7-022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B2018-00404 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-4818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-1492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B18-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-0551 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B18-14 |
| filingDate |
2018-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18f76a7e3f315730ec9a3b7d9f085fda
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfd32b00fb4226e36d44a2e1fa968c22 |
| publicationDate |
2019-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019009077-A1 |
| titleOfInvention |
Methods for treating anxiety disorders in patients via renal neuromodulation |
| abstract |
Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021267661-A1 |
| priorityDate |
2017-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |